GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ulisse Biomed SpA (MIL:UBM) » Definitions » Equity-to-Asset

Ulisse Biomed SpA (MIL:UBM) Equity-to-Asset : 0.87 (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Ulisse Biomed SpA Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Ulisse Biomed SpA's Total Stockholders Equity for the quarter that ended in Dec. 2024 was €23.67 Mil. Ulisse Biomed SpA's Total Assets for the quarter that ended in Dec. 2024 was €27.26 Mil. Therefore, Ulisse Biomed SpA's Equity to Asset Ratio for the quarter that ended in Dec. 2024 was 0.87.

The historical rank and industry rank for Ulisse Biomed SpA's Equity-to-Asset or its related term are showing as below:

MIL:UBM' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.43   Med: 0.87   Max: 0.95
Current: 0.87

During the past 7 years, the highest Equity to Asset Ratio of Ulisse Biomed SpA was 0.95. The lowest was 0.43. And the median was 0.87.

MIL:UBM's Equity-to-Asset is ranked better than
77.86% of 1504 companies
in the Biotechnology industry
Industry Median: 0.67 vs MIL:UBM: 0.87

Ulisse Biomed SpA Equity-to-Asset Historical Data

The historical data trend for Ulisse Biomed SpA's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ulisse Biomed SpA Equity-to-Asset Chart

Ulisse Biomed SpA Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Equity-to-Asset
Get a 7-Day Free Trial 0.84 0.90 0.91 0.95 0.87

Ulisse Biomed SpA Semi-Annual Data
Dec18 Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.91 0.88 0.95 0.87 0.87

Competitive Comparison of Ulisse Biomed SpA's Equity-to-Asset

For the Biotechnology subindustry, Ulisse Biomed SpA's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ulisse Biomed SpA's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ulisse Biomed SpA's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Ulisse Biomed SpA's Equity-to-Asset falls into.


;
;

Ulisse Biomed SpA Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Ulisse Biomed SpA's Equity to Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Equity to Asset (A: Dec. 2024 )=Total Stockholders Equity/Total Assets
=23.67/27.259
=0.87

Ulisse Biomed SpA's Equity to Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

Equity to Asset (Q: Dec. 2024 )=Total Stockholders Equity/Total Assets
=23.67/27.259
=0.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ulisse Biomed SpA  (MIL:UBM) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Ulisse Biomed SpA Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Ulisse Biomed SpA's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Ulisse Biomed SpA Business Description

Traded in Other Exchanges
N/A
Address
Area Science Park - SS14 km.163, 5, Basovizza, ITA, 34149
Ulisse Biomed SpA is a healthcare biotech company. It is engaged in developing medical diagnostics, theranostics, and therapeutics solutions. The company has three technology platforms, namely, Sagitta for molecular diagnostics, NanoHybrid for theranostics and diagnostics, and Aptavir for therapeutics.

Ulisse Biomed SpA Headlines

No Headlines